Recent advances in chemotherapy for advanced gastric cancer

作     者：Jong Gwang Kim Ho Young Chung Wansik Yu 

作者机构：Department of Oncology/HematologyKyungpook National University Hospital Kyungpook National University School of Medicine Department of SurgeryKyungpook National University Hospital 

出 版 物：《World Journal of Gastrointestinal Oncology》 (世界胃肠肿瘤学杂志（英文版）（电子版）)

年 卷 期：2010年第2卷第7期

页      面：287-294页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Gastric cancer Prognosis Chemotherapy Cytotoxic agents Targeted agents 

摘      要：Although medical treatment has been shown to improve quality of life and prolong survival,no significant progress has been made in the treatment of advanced gastric cancer(AGC)within the last two ***,the choice of optimum standard first-line chemotherapy regimen for AGC remains debatable,and most responses to chemotherapy are partial and of short duration,with a median survival of approximately 7-11 mo and survival at 2 years rarely more than 10%.Recently,remarkable progress in tumor biology has led to the development of new agents that target critical aspects of oncogenic *** AGC,several molecular targeting agents are now under evaluation in international randomized studies,and trastuzumab,an anti-HER2 monoclonal antibody,has shown antitumor activity against HER-2 positive ***, this benefit is limited to only about 20%of patients with AGC(patients with HER-2 positive AGC).Therefore,there remains a critical need for both the development of more effective agents and the identification of predictive and prognostic molecular markers to select those patients who will benefit most from specific chemotherapeutic regimens and targeted therapies.